SA
PBLS logo
Parabilis Medicines, Inc.(PBLS)
Closing price · checked 8:17 PM ETAbout this dataData status
$27.63▼-0.84 (-2.97%)
Extended:$27.63+0.00 (+0.00%)· 8:17 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.4 · elevated volatility

Overview →

Parabilis Medicines, Inc. (PBLS)

R&D Expense Growth

24.55%

Fiscal year · Period ending:

PBLS logo

PBLS R&D Expense Growth

Latest reported24.55%
PBLS FY R&D Growth (YoY) (0.00% → 24.55%)
High-resolution chart · PNG

What is r&d expense growth?

Year-over-year research & development expense growth.

PBLS r&d expense growth history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Parabilis Medicines, Inc. R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
24.5505%
0%

Frequently asked questions: PBLS r&d expense growth

What is Parabilis Medicines, Inc. (PBLS)'s current r&d expense growth?

Parabilis Medicines, Inc. (PBLS)'s latest reported r&d expense growth (Fiscal year) is 24.55% as of Dec 31, 2025. Year-over-year research & development expense growth.

How much historical r&d expense growth data is available for PBLS?

Stock Alarm Pro provides 2 dated annual fiscal periods observations for Parabilis Medicines, Inc. (PBLS)'s r&d expense growth, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare PBLS's r&d expense growth to peers or set an alert?

You can open PBLS's r&d expense growth in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on PBLS delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.